Clinical Trial Update: OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE) [Phase 3]

View source ↗

Summary

Phase 3 trial results update for donidalorsen in hereditary angioedema (HAE) from the OASIS-HAE study, with results posted in March 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• Donidalorsen (ISIS 721744 / IONIS-PKK-LRx) (donidalorsen)

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Hereditary Angioedema | Phase 3 | Status: COMPLETED | Results posted: 2025-03-06